Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References FTP Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) RatMine GViewer (Genome Viewer) Overgo Probe Designer ACP Haplotyper Genome Scanner
Aging & Age-Related Disease Cancer Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:pyrrolidin-2-ones
go back to main search page
Accession:CHEBI:74223 term browser browse the term
Definition:A pyrrolidinone in which the oxo group is at position 2 of the pyrrolidine ring.
Synonyms:related_synonym: 2-pyrrolidinones;   2-pyrrolidones;   Formula=C4NOR7;   SMILES=[*]N1C(=O)C([*])([*])C([*])([*])C1([*])[*];   pyrrolidine-2-ones

show annotations for term's descendants           Sort by:
 
(-)-cotinine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ahrr aryl-hydrocarbon receptor repressor affects methylation ISO Cotinine affects the methylation of AHRR gene CTD PMID:22851337 NCBI chr 1:31,603,297...31,698,329
Ensembl chr 1:31,603,297...31,698,329 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases phosphorylation
multiple interactions		 ISO Cotinine results in increased phosphorylation of AKT1 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cotinine results in increased phosphorylation of AKT1 protein]		 CTD PMID:22687995 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO Cotinine inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein] CTD PMID:22687995 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204 		JBrowse link
G Casp7 caspase 7 multiple interactions ISO Cotinine inhibits the reaction [Doxorubicin results in increased activity of CASP7 protein] CTD PMID:22687995 NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774 		JBrowse link
G Ccnd1 cyclin D1 increases expression ISO Cotinine results in increased expression of CCND1 protein CTD PMID:31678612 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325 		JBrowse link
G Cd68 Cd68 molecule multiple interactions EXP [Nicotine results in increased abundance of Cotinine] which results in increased expression of CD68 mRNA CTD PMID:29617909 NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640 		JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions EXP [Nicotine results in increased abundance of Cotinine] which results in increased expression of CEBPA protein CTD PMID:29617909 NCBI chr 1:91,363,492...91,366,164
Ensembl chr 1:91,363,492...91,366,164 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions EXP [Nicotine results in increased abundance of Cotinine] which results in increased expression of CEBPB mRNA CTD PMID:29617909 NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910 		JBrowse link
G Chrna7 cholinergic receptor nicotinic alpha 7 subunit increases response to substance
multiple interactions		 ISO CHRNA7 protein mutant form results in increased susceptibility to Cotinine
Cotinine binds to and results in increased activity of CHRNA7 protein		 CTD PMID:10082212 NCBI chr 1:123,897,341...124,039,263
Ensembl chr 1:123,899,657...124,039,196 		JBrowse link
G Cntnap2 contactin associated protein 2 affects methylation ISO Cotinine affects the methylation of CNTNAP2 gene CTD PMID:22851337 NCBI chr 4:74,700,539...77,025,463 JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 affects methylation ISO Cotinine affects the methylation of CYP1A1 gene CTD PMID:22851337 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147 		JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 increases activity
decreases activity		 ISO Cotinine results in increased activity of CYP1A2 protein
Cotinine results in decreased activity of CYP1A2 protein		 CTD PMID:15916432, PMID:16203240 NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301 		JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 increases abundance
multiple interactions		 EXP CYP2B1 protein results in increased abundance of Cotinine
[Nicotine results in increased expression of CYP2B1 protein] which results in increased abundance of Cotinine		 CTD PMID:10799646 NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783 		JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 increases chemical synthesis ISO CYP2B6 protein results in increased chemical synthesis of Cotinine CTD PMID:12488541 NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615 		JBrowse link
G Ext1 exostosin glycosyltransferase 1 affects methylation ISO Cotinine affects the methylation of EXT1 gene CTD PMID:22851337 NCBI chr 7:92,605,008...92,881,392
Ensembl chr 7:92,605,728...92,882,068 		JBrowse link
G Gfi1 growth factor independent 1 transcriptional repressor affects methylation ISO Cotinine affects the methylation of GFI1 gene CTD PMID:22851337 NCBI chr14:3,058,035...3,073,332
Ensembl chr14:3,058,993...3,068,371 		JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP [Nicotine results in increased abundance of Cotinine] which results in increased expression of IL1B mRNA CTD PMID:29617909 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726 		JBrowse link
G Il6 interleukin 6 multiple interactions EXP [Nicotine results in increased abundance of Cotinine] which results in increased expression of IL6 mRNA CTD PMID:29617909 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation ISO Cotinine results in decreased phosphorylation of MAPK1 protein CTD PMID:31678612 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation ISO Cotinine results in decreased phosphorylation of MAPK3 protein CTD PMID:31678612 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975 		JBrowse link
G Mki67 marker of proliferation Ki-67 increases expression EXP Cotinine results in increased expression of MKI67 protein CTD PMID:31678612 NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454 		JBrowse link
G Myo1g myosin IG affects methylation ISO Cotinine affects the methylation of MYO1G gene CTD PMID:22851337 NCBI chr14:86,781,243...86,796,393
Ensembl chr14:86,781,202...86,796,378 		JBrowse link
G Nat1 N-acetyltransferase 1 multiple interactions
affects abundance		 ISO NAT1 gene polymorphism affects the reaction [Tobacco Smoke Pollution results in increased abundance of Cotinine]
NAT1 gene polymorphism affects the abundance of Cotinine		 CTD PMID:25156213 NCBI chr16:23,970,742...23,991,573
Ensembl chr16:23,970,743...23,991,573 		JBrowse link
G Pnpla2 patatin-like phospholipase domain containing 2 multiple interactions EXP [Nicotine results in increased abundance of Cotinine] which results in increased expression of PNPLA2 mRNA; [Nicotine results in increased abundance of Cotinine] which results in increased expression of PNPLA2 protein CTD PMID:29617909 NCBI chr 1:214,434,638...214,439,720
Ensembl chr 1:214,434,626...214,439,720 		JBrowse link
G Runx1 RUNX family transcription factor 1 affects methylation ISO Cotinine affects the methylation of RUNX1 gene CTD PMID:22851337 NCBI chr11:32,765,147...33,003,061
Ensembl chr11:32,769,165...33,003,021 		JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions EXP [Nicotine results in increased abundance of Cotinine] which results in increased expression of SOD1 mRNA; [Nicotine results in increased abundance of Cotinine] which results in increased expression of SOD1 protein CTD PMID:29617909 NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions EXP [Nicotine results in increased abundance of Cotinine] which results in increased expression of SOD2 protein CTD PMID:29617909 NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions EXP [Nicotine results in increased abundance of Cotinine] which results in increased expression of SREBF1 mRNA CTD PMID:29617909 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 increases phosphorylation ISO Cotinine results in increased phosphorylation of STAT3 protein CTD PMID:31678612 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233 		JBrowse link
G Tnf tumor necrosis factor multiple interactions EXP [Nicotine results in increased abundance of Cotinine] which results in increased expression of TNF mRNA CTD PMID:29617909 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 		JBrowse link
G Ttc7b tetratricopeptide repeat domain 7B affects methylation ISO Cotinine affects the methylation of TTC7B gene CTD PMID:22851337 NCBI chr 6:124,316,444...124,528,058
Ensembl chr 6:124,316,445...124,429,701 		JBrowse link
G Ugt1a5 UDP glucuronosyltransferase family 1 member A5 increases glucuronidation ISO UGT1A4 protein results in increased glucuronidation of Cotinine CTD PMID:14570768, PMID:16141602 NCBI chr 9:95,256,628...95,302,822
Ensembl chr 9:95,161,157...95,302,822 		JBrowse link
G Ugt1a9 UDP glucuronosyltransferase family 1 member A9 increases glucuronidation ISO UGT1A9 protein results in increased glucuronidation of Cotinine CTD PMID:16141602 NCBI chr 9:95,161,157...95,302,822
Ensembl chr 9:95,161,157...95,302,822 		JBrowse link
5-oxo-L-proline term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Dek DEK proto-oncogene multiple interactions ISO DEK protein results in decreased chemical synthesis of and results in increased uptake of Pyrrolidonecarboxylic Acid CTD PMID:28558019 NCBI chr17:17,965,872...17,987,836
Ensembl chr17:17,965,881...17,987,834 		JBrowse link
G Ins2 insulin 2 multiple interactions ISO [1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of Pyrrolidonecarboxylic Acid analog CTD PMID:26820058 NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034 		JBrowse link
aniracetam term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ces1d carboxylesterase 1D increases hydrolysis ISO CES1 protein results in increased hydrolysis of aniracetam CTD PMID:9300133 NCBI chr19:15,195,514...15,239,827
Ensembl chr19:15,033,108...15,239,821 		JBrowse link
G Ces2h carboxylesterase 2H increases hydrolysis ISO CES2 protein results in increased hydrolysis of aniracetam CTD PMID:9300133 NCBI chr19:37,052,555...37,067,176
Ensembl chr19:37,052,556...37,067,156 		JBrowse link
doxapram term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Crh corticotropin releasing hormone increases expression EXP Doxapram results in increased expression of CRH mRNA; Doxapram results in increased expression of CRH protein CTD PMID:16269353 NCBI chr 2:104,459,999...104,461,863
Ensembl chr 2:104,459,999...104,461,863 		JBrowse link
G Prl prolactin increases expression ISO Doxapram results in increased expression of PRL protein CTD PMID:15741000 NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299 		JBrowse link
levetiracetam term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
increases expression
increases transport
decreases activity		 EXP
ISO		 Amino Acids, Peptides, and Proteins inhibits the reaction [Levetiracetam results in increased expression of ABCB1 protein]
ABCB1A protein results in increased transport of Levetiracetam
Levetiracetam results in decreased activity of ABCB1 protein		 CTD PMID:17045309, PMID:18408562, PMID:18473823 NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515 		JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 increases expression EXP Levetiracetam results in increased expression of ABCC1 protein CTD PMID:18473823 NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196 		JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression EXP Levetiracetam results in increased expression of ABCC2 protein CTD PMID:18473823 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252 		JBrowse link
G Acvrl1 activin A receptor like type 1 decreases expression EXP Levetiracetam results in decreased expression of ACVRL1 mRNA CTD PMID:20345932 NCBI chr 7:142,769,942...142,787,336
Ensembl chr 7:142,776,252...142,787,335 		JBrowse link
G Arhgef1 Rho guanine nucleotide exchange factor 1 decreases expression EXP Levetiracetam results in decreased expression of ARHGEF1 mRNA CTD PMID:20345932 NCBI chr 1:81,769,212...81,797,237
Ensembl chr 1:81,779,380...81,797,236 		JBrowse link
G Cacnb1 calcium voltage-gated channel auxiliary subunit beta 1 decreases expression EXP Levetiracetam results in decreased expression of CACNB1 mRNA CTD PMID:20345932 NCBI chr10:85,954,138...85,974,764
Ensembl chr10:85,954,138...85,974,651 		JBrowse link
G Cat catalase multiple interactions ISO Levetiracetam inhibits the reaction [Pilocarpine results in increased activity of CAT protein] CTD PMID:17205390 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058 		JBrowse link
G Ccnh cyclin H increases expression EXP Levetiracetam results in increased expression of CCNH mRNA CTD PMID:20345932 NCBI chr 2:13,593,100...13,613,910
Ensembl chr 2:13,593,100...13,613,910 		JBrowse link
G Chrm2 cholinergic receptor, muscarinic 2 increases activity
decreases expression		 ISO Levetiracetam results in increased activity of CHRM2 protein
Levetiracetam results in decreased expression of CHRM2 protein		 CTD PMID:15967574 NCBI chr 4:64,089,028...64,091,090
Ensembl chr 4:64,088,900...64,091,090 		JBrowse link
G Cxcr3 C-X-C motif chemokine receptor 3 increases expression EXP Levetiracetam results in increased expression of CXCR3 mRNA CTD PMID:20345932 NCBI chr  X:71,614,346...71,616,997
Ensembl chr  X:71,614,346...71,616,997 		JBrowse link
G Cyp17a1 cytochrome P450, family 17, subfamily a, polypeptide 1 decreases expression ISO Levetiracetam results in decreased expression of CYP17A1 mRNA CTD PMID:19566492 NCBI chr 1:266,422,127...266,429,947
Ensembl chr 1:266,422,132...266,428,239 		JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 decreases expression ISO Levetiracetam results in decreased expression of CYP19A1 mRNA CTD PMID:19566492 NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408 		JBrowse link
G Dao D-amino-acid oxidase increases expression EXP Levetiracetam results in increased expression of DAO mRNA CTD PMID:20345932 NCBI chr12:48,353,691...48,373,647
Ensembl chr12:48,354,196...48,365,784 		JBrowse link
G Dbp D-box binding PAR bZIP transcription factor decreases expression EXP Levetiracetam results in decreased expression of DBP mRNA CTD PMID:20345932 NCBI chr 1:101,687,896...101,692,845
Ensembl chr 1:101,687,855...101,692,846 		JBrowse link
G Des desmin increases expression EXP Levetiracetam results in increased expression of DES mRNA CTD PMID:20345932 NCBI chr 9:82,556,574...82,564,288
Ensembl chr 9:82,556,573...82,564,294 		JBrowse link
G Gle1 GLE1 RNA export mediator increases expression EXP Levetiracetam results in increased expression of GLE1 mRNA CTD PMID:20345932 NCBI chr 3:8,498,098...8,530,218
Ensembl chr 3:8,498,122...8,526,771 		JBrowse link
G Hcn2 hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2 decreases expression EXP Levetiracetam results in decreased expression of HCN2 mRNA CTD PMID:20345932 NCBI chr 7:12,851,730...12,870,087
Ensembl chr 7:12,851,739...12,874,215 		JBrowse link
G Hdac10 histone deacetylase 10 decreases expression EXP Levetiracetam results in decreased expression of HDAC10 mRNA CTD PMID:20345932 NCBI chr 7:130,102,335...130,109,036
Ensembl chr 7:130,102,347...130,107,437 		JBrowse link
G Hsd3b2 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 decreases expression ISO Levetiracetam results in decreased expression of HSD3B2 mRNA CTD PMID:19566492 NCBI chr 2:200,712,895...200,722,429
Ensembl chr 2:202,341,422...202,350,929 		JBrowse link
G Kcna4 potassium voltage-gated channel subfamily A member 4 increases expression EXP Levetiracetam results in increased expression of KCNA4 mRNA CTD PMID:20345932 NCBI chr 3:98,293,295...98,300,763
Ensembl chr 3:98,297,554...98,300,680 		JBrowse link
G Kctd3 potassium channel tetramerization domain containing 3 increases expression EXP Levetiracetam results in increased expression of KCTD3 mRNA CTD PMID:20345932 NCBI chr13:107,433,588...107,471,843
Ensembl chr13:107,433,588...107,471,843 		JBrowse link
G Khdrbs2 KH RNA binding domain containing, signal transduction associated 2 increases expression EXP Levetiracetam results in increased expression of KHDRBS2 mRNA CTD PMID:20345932 NCBI chr 9:39,501,431...40,008,707
Ensembl chr 9:39,539,530...40,008,680 		JBrowse link
G Lap3 leucine aminopeptidase 3 increases expression EXP Levetiracetam results in increased expression of LAP3 mRNA CTD PMID:20345932 NCBI chr14:70,102,813...70,121,797
Ensembl chr14:70,102,814...70,121,797 		JBrowse link
G Lsm1 LSM1 homolog, mRNA degradation associated increases expression EXP Levetiracetam results in increased expression of LSM1 mRNA CTD PMID:20345932 NCBI chr16:71,046,475...71,057,883
Ensembl chr16:71,046,475...71,057,883 		JBrowse link
G Mettl7b methyltransferase like 7B increases expression EXP Levetiracetam results in increased expression of METTL7B mRNA CTD PMID:20345932 NCBI chr 7:3,383,876...3,386,522
Ensembl chr 7:3,383,879...3,386,522 		JBrowse link
G Nap1l2 nucleosome assembly protein 1-like 2 increases expression EXP Levetiracetam results in increased expression of NAP1L2 mRNA CTD PMID:20345932 NCBI chr  X:73,997,274...73,999,677 JBrowse link
G Ngly1 N-glycanase 1 increases expression EXP Levetiracetam results in increased expression of NGLY1 mRNA CTD PMID:20345932 NCBI chr15:10,405,453...10,455,973
Ensembl chr15:10,405,164...10,455,956 		JBrowse link
G Phldb1 pleckstrin homology-like domain, family B, member 1 decreases expression EXP Levetiracetam results in decreased expression of PHLDB1 mRNA CTD PMID:20345932 NCBI chr 8:48,997,189...49,045,176
Ensembl chr 8:48,997,184...49,045,154 		JBrowse link
G Pon1 paraoxonase 1 affects activity ISO Levetiracetam affects the activity of PON1 protein CTD PMID:28032682 NCBI chr 4:30,249,749...30,276,297
Ensembl chr 4:30,249,742...30,276,372 		JBrowse link
G Prkx protein kinase, X-linked increases expression EXP Levetiracetam results in increased expression of PRKX mRNA CTD PMID:20345932 NCBI chr  X:45,080,963...45,125,095
Ensembl chr  X:45,080,963...45,124,270 		JBrowse link
G Psip1 PC4 and SFRS1 interacting protein 1 increases expression EXP Levetiracetam results in increased expression of PSIP1 mRNA CTD PMID:20345932 NCBI chr 5:101,555,691...101,588,659
Ensembl chr 5:101,555,694...101,588,598 		JBrowse link
G Serinc1 serine incorporator 1 increases expression EXP Levetiracetam results in increased expression of SERINC1 mRNA CTD PMID:20345932 NCBI chr20:38,966,016...38,985,056
Ensembl chr20:38,967,238...38,985,036 		JBrowse link
G Slc23a2 solute carrier family 23 member 2 increases expression EXP Levetiracetam results in increased expression of SLC23A2 mRNA CTD PMID:20345932 NCBI chr 3:124,632,491...124,842,225
Ensembl chr 3:124,632,492...124,724,252 		JBrowse link
G Slc4a7 solute carrier family 4 member 7 increases expression EXP Levetiracetam results in increased expression of SLC4A7 mRNA CTD PMID:20345932 NCBI chr15:11,832,611...11,912,923
Ensembl chr15:11,836,286...11,912,916 		JBrowse link
G Smc2 structural maintenance of chromosomes 2 increases expression EXP Levetiracetam results in increased expression of SMC2 mRNA CTD PMID:20345932 NCBI chr 5:68,717,509...68,764,080
Ensembl chr 5:68,717,519...68,763,850 		JBrowse link
G Star steroidogenic acute regulatory protein decreases expression ISO Levetiracetam results in decreased expression of STAR mRNA CTD PMID:19566492 NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847 		JBrowse link
G Tent2 terminal nucleotidyltransferase 2 increases expression EXP Levetiracetam results in increased expression of TENT2 mRNA CTD PMID:20345932 NCBI chr 2:22,746,290...22,798,252
Ensembl chr 2:22,747,547...22,798,214 		JBrowse link
G Trdmt1 tRNA aspartic acid methyltransferase 1 decreases expression EXP Levetiracetam results in decreased expression of TRDMT1 mRNA CTD PMID:20345932 NCBI chr17:80,824,652...80,859,585
Ensembl chr17:80,826,846...80,860,195 		JBrowse link
G Vars2 valyl-tRNA synthetase 2, mitochondrial decreases expression EXP Levetiracetam results in decreased expression of VARS2 mRNA CTD PMID:20345932 NCBI chr20:3,588,462...3,599,514
Ensembl chr20:3,588,497...3,599,514 		JBrowse link
G Xrcc1 X-ray repair cross complementing 1 decreases expression EXP Levetiracetam results in decreased expression of XRCC1 mRNA CTD PMID:20345932 NCBI chr 1:81,412,635...81,441,680
Ensembl chr 1:81,413,353...81,441,678 		JBrowse link
G Zfp266 zinc finger protein 266 increases expression EXP Levetiracetam results in increased expression of ZFP266 mRNA CTD PMID:20345932 NCBI chr 8:21,511,831...21,543,275
Ensembl chr 8:21,511,839...21,523,540 		JBrowse link
N-Vinyl-2-pyrrolidone term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of ABCC2 mRNA CTD PMID:22037397 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252 		JBrowse link
G Abcc3 ATP binding cassette subfamily C member 3 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of ABCC3 mRNA CTD PMID:22037397 NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of AKT1 mRNA CTD PMID:22037397 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258 		JBrowse link
G Akt2 AKT serine/threonine kinase 2 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of AKT2 mRNA CTD PMID:22037397 NCBI chr 1:84,400,939...84,451,223
Ensembl chr 1:84,411,726...84,450,162 		JBrowse link
G Bcar1 BCAR1 scaffold protein, Cas family member multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of BCAR1 mRNA CTD PMID:22037397 NCBI chr19:43,932,543...43,967,452
Ensembl chr19:43,932,554...43,955,783 		JBrowse link
G Capn1 calpain 1 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CAPN1 mRNA CTD PMID:22037397 NCBI chr 1:221,346,081...221,370,965
Ensembl chr 1:221,346,066...221,370,322 		JBrowse link
G Crk CRK proto-oncogene, adaptor protein multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CRK mRNA CTD PMID:22037397 NCBI chr10:63,829,731...63,855,999
Ensembl chr10:63,829,807...63,852,780 		JBrowse link
G Csnk1d casein kinase 1, delta multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CSNK1D mRNA CTD PMID:22037397 NCBI chr10:110,147,786...110,182,413
Ensembl chr10:110,148,600...110,182,408 		JBrowse link
G Csnk1e casein kinase 1, epsilon multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CSNK1E mRNA CTD PMID:22037397 NCBI chr 7:120,651,976...120,675,559
Ensembl chr 7:120,651,881...120,672,359 		JBrowse link
G Csnk2a1 casein kinase 2 alpha 1 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CSNK2A1 mRNA CTD PMID:22037397 NCBI chr 3:147,713,808...147,760,375
Ensembl chr 3:147,713,821...147,757,862 		JBrowse link
G Csnk2a2 casein kinase 2 alpha 2 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CSNK2A2 mRNA CTD PMID:22037397 NCBI chr19:9,972,537...10,012,043
Ensembl chr19:9,972,537...10,012,043 		JBrowse link
G Cyp2b1 cytochrome P450, family 2, subfamily b, polypeptide 1 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CYP2B1 mRNA CTD PMID:22037397 NCBI chr 7:99,142,431...99,183,540
Ensembl chr 7:99,142,450...99,181,783 		JBrowse link
G Cyp3a23-3a1 cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CYP3A23-3A1 mRNA CTD PMID:22037397 NCBI chr12:11,053,888...11,082,742
Ensembl chr12:11,655,402...11,733,136 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of CYP3A9 mRNA CTD PMID:22037397 NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399 		JBrowse link
G Ddr1 discoidin domain receptor tyrosine kinase 1 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of DDR1 mRNA CTD PMID:22037397 NCBI chr20:3,553,430...3,574,959
Ensembl chr20:3,552,929...3,575,780 		JBrowse link
G Foxg1 forkhead box G1 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of FOXG1 mRNA CTD PMID:22037397 NCBI chr 6:69,971,227...69,974,037
Ensembl chr 6:69,971,227...69,974,037 		JBrowse link
G Hdac1 histone deacetylase 1 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which affects the expression of HDAC1 mRNA CTD PMID:22037397 NCBI chr 5:147,716,664...147,743,723
Ensembl chr 5:147,716,664...147,743,723 		JBrowse link
G Ilk integrin-linked kinase multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of ILK mRNA CTD PMID:22037397 NCBI chr 1:170,578,941...170,585,192
Ensembl chr 1:170,578,889...170,585,189 		JBrowse link
G Lef1 lymphoid enhancer binding factor 1 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of LEF1 mRNA CTD PMID:22037397 NCBI chr 2:236,232,115...236,345,061
Ensembl chr 2:236,233,239...236,345,056 		JBrowse link
G Mdm2 MDM2 proto-oncogene multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which affects the expression of MDM2 mRNA CTD PMID:22037397 NCBI chr 7:60,719,060...60,743,618
Ensembl chr 7:60,719,066...60,743,328 		JBrowse link
G Pik3r2 phosphoinositide-3-kinase regulatory subunit 2 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of PIK3R2 mRNA CTD PMID:22037397 NCBI chr16:20,415,109...20,424,982
Ensembl chr16:20,416,432...20,424,980 		JBrowse link
G Ppp2r1a protein phosphatase 2 scaffold subunit A alpha multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of PPP2R1A mRNA CTD PMID:22037397 NCBI chr 1:60,717,386...60,736,629
Ensembl chr 1:60,717,386...60,736,609 		JBrowse link
G Slc5a5 solute carrier family 5 member 5 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which affects the expression of SLC5A5 mRNA CTD PMID:22037397 NCBI chr16:20,297,414...20,307,401
Ensembl chr16:20,297,414...20,307,400 		JBrowse link
G Tcf3 transcription factor 3 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of TCF3 mRNA CTD PMID:22037397 NCBI chr 7:12,146,642...12,168,400
Ensembl chr 7:12,144,162...12,168,410 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of TGFB1 mRNA CTD PMID:22037397 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199 		JBrowse link
G Tgfbr2 transforming growth factor, beta receptor 2 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of TGFBR2 mRNA CTD PMID:22037397 NCBI chr 8:124,310,288...124,399,345
Ensembl chr 8:124,312,754...124,399,494 		JBrowse link
G Tpo thyroid peroxidase multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of TPO mRNA CTD PMID:22037397 NCBI chr 6:49,020,918...49,089,855
Ensembl chr 6:49,021,044...49,089,855 		JBrowse link
G Tshb thyroid stimulating hormone subunit beta multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of TSHB protein CTD PMID:22037397 NCBI chr 2:205,207,799...205,215,199
Ensembl chr 2:205,207,799...205,212,681 		JBrowse link
G Ugt2b17 UDP glucuronosyltransferase family 2 member B17 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of UGT2B1 mRNA CTD PMID:22037397 NCBI chr14:22,724,399...22,736,148
Ensembl chr14:22,724,070...22,825,444 		JBrowse link
G Wnt4 Wnt family member 4 multiple interactions EXP [N-vinyl-2-pyrrolidinone binds to N-vinyl-2-pyrrolidinone] which results in increased expression of WNT4 mRNA CTD PMID:22037397 NCBI chr 5:155,649,238...155,668,065
Ensembl chr 5:155,649,217...155,672,579 		JBrowse link
rolipram term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adcyap1 adenylate cyclase activating polypeptide 1 multiple interactions ISO Rolipram promotes the reaction [ADCYAP1 protein affects the secretion of Acids] CTD PMID:20388963 NCBI chr 9:121,705,897...121,725,736
Ensembl chr 9:121,706,979...121,725,716 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
increases phosphorylation		 EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Rolipram promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein]]; RAPGEF3 mutant form inhibits the reaction [Rolipram results in increased phosphorylation of AKT1 protein]; Rolipram promotes the reaction [Nitroprusside results in increased phosphorylation of AKT1 protein] CTD PMID:18276108 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258 		JBrowse link
G Ap2m1 adaptor related protein complex 2 subunit mu 1 multiple interactions ISO Rolipram inhibits the reaction [NTRK2 protein binds to AP2M1 protein] CTD PMID:31631060 NCBI chr11:84,041,184...84,047,542
Ensembl chr11:84,041,184...84,047,546 		JBrowse link
G Areg amphiregulin increases expression ISO Rolipram results in increased expression of AREG mRNA CTD PMID:15284208 NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP Rolipram inhibits the reaction [Manganese results in increased expression of BAX protein] CTD PMID:31161640 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions EXP Rolipram inhibits the reaction [Manganese results in decreased expression of BCL2 protein] CTD PMID:31161640 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374 		JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions
increases expression		 EXP Rolipram inhibits the reaction [Manganese results in decreased expression of BDNF protein]; Rolipram promotes the reaction [Imipramine results in increased expression of BDNF mRNA]
Rolipram results in increased expression of BDNF mRNA		 CTD PMID:8601816, PMID:31161640 NCBI chr 3:100,768,637...100,819,216
Ensembl chr 3:100,768,637...100,819,210 		JBrowse link
G Casp8 caspase 8 multiple interactions EXP Rolipram inhibits the reaction [Manganese results in increased activity of CASP8 protein] CTD PMID:31161640 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions EXP Rolipram inhibits the reaction [Oxygen results in increased expression of CCL2 protein] CTD PMID:18941502 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870 		JBrowse link
G Ccl3 C-C motif chemokine ligand 3 multiple interactions ISO Rolipram inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; Rolipram inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein] CTD PMID:9863660 NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066 		JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions EXP Rolipram promotes the reaction [FSHB protein results in increased expression of CEBPB protein] CTD PMID:25253736 NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910 		JBrowse link
G Cftr CF transmembrane conductance regulator multiple interactions
increases activity
decreases activity		 ISO Rolipram promotes the reaction [CFTR protein affects the secretion of Chlorides]
Rolipram results in increased activity of CFTR protein
Rolipram results in decreased activity of CFTR protein		 CTD PMID:12714375, PMID:15611099 NCBI chr 4:42,693,263...42,860,679
Ensembl chr 4:42,692,836...42,860,676 		JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions
increases phosphorylation
increases expression		 EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Rolipram promotes the reaction [Nitroprusside results in increased phosphorylation of CREB1 protein]]; Rolipram inhibits the reaction [Manganese results in decreased phosphorylation of CREB1 protein]; Rolipram promotes the reaction [Imipramine results in increased expression of CREB1 mRNA]; Rolipram promotes the reaction [Nitroprusside results in increased phosphorylation of CREB1 protein]
Rolipram results in increased phosphorylation of CREB1 protein
Rolipram results in increased expression of CREB1 mRNA		 CTD PMID:8601816, PMID:10908723, PMID:18276108, PMID:31161640 NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435 		JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 decreases secretion ISO Rolipram results in decreased secretion of CXCL10 protein CTD PMID:17996064 NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930 		JBrowse link
G Edn1 endothelin 1 increases activity EXP Rolipram results in increased activity of EDN1 protein CTD PMID:15464066 NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324 		JBrowse link
G Epx eosinophil peroxidase multiple interactions EXP Rolipram inhibits the reaction [sephadex results in increased expression of EPX protein] CTD PMID:10850854 NCBI chr10:75,160,690...75,171,774
Ensembl chr10:75,160,690...75,171,774 		JBrowse link
G Fshb follicle stimulating hormone subunit beta multiple interactions EXP Rolipram promotes the reaction [FSHB protein results in increased expression of CEBPB protein]; Rolipram promotes the reaction [FSHB protein results in increased expression of STAR mRNA] CTD PMID:25253736 NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131 		JBrowse link
G Il10 interleukin 10 decreases secretion ISO Rolipram results in decreased secretion of IL10 protein CTD PMID:9819297 NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392 		JBrowse link
G Il13 interleukin 13 decreases expression
decreases secretion		 ISO Rolipram results in decreased expression of IL13 mRNA
Rolipram results in decreased secretion of IL13 protein		 CTD PMID:16083514 NCBI chr10:38,982,909...38,985,466
Ensembl chr10:38,982,909...38,985,466 		JBrowse link
G Il18 interleukin 18 multiple interactions ISO Rolipram inhibits the reaction [Picryl Chloride results in increased expression of IL18 protein] CTD PMID:16442096 NCBI chr 8:55,009,666...55,016,286
Ensembl chr 8:54,993,859...55,016,299 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO
EXP		 Rolipram inhibits the reaction [Picryl Chloride results in increased expression of IL1B protein]
Rolipram promotes the reaction [IL1B protein results in increased abundance of Cyclic AMP]
Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of IL1B mRNA]		 CTD PMID:8904084, PMID:16442096, PMID:18710439 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726 		JBrowse link
G Il4 interleukin 4 multiple interactions ISO Rolipram inhibits the reaction [Picryl Chloride results in increased expression of IL4 protein] CTD PMID:16442096 NCBI chr10:38,963,979...38,969,531
Ensembl chr10:38,963,979...38,969,531 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO Rolipram inhibits the reaction [Picryl Chloride results in increased expression of IL6 protein]
Rolipram promotes the reaction [TNF protein results in increased expression of IL6 mRNA]		 CTD PMID:16442096, PMID:24771768 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807 		JBrowse link
G Itgam integrin subunit alpha M multiple interactions ISO N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Rolipram inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein]]; Rolipram inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of ITGAM protein] CTD PMID:21457779 NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960 		JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 decreases activity ISO Rolipram results in decreased activity of KCNH2 protein CTD PMID:17146843 NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253 		JBrowse link
G Ltc4s leukotriene C4 synthase decreases secretion ISO Rolipram results in decreased secretion of LTC4S protein CTD PMID:16083514 NCBI chr10:35,736,486...35,743,088
Ensembl chr10:35,737,664...35,739,625 		JBrowse link
G Mpo myeloperoxidase multiple interactions ISO
EXP		 Rolipram inhibits the reaction [Picryl Chloride results in increased activity of MPO protein]
Rolipram inhibits the reaction [Cyclophosphamide results in increased activity of MPO protein]; Rolipram inhibits the reaction [Indomethacin results in increased activity of MPO protein]		 CTD PMID:14567935, PMID:16442096, PMID:18710439 NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260 		JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions EXP Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 mRNA]; Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of NOS2 protein] CTD PMID:18710439 NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190 		JBrowse link
G Ntrk2 neurotrophic receptor tyrosine kinase 2 increases expression
multiple interactions		 EXP
ISO		 Rolipram results in increased expression of NTRK2 mRNA
Rolipram inhibits the reaction [NTRK2 protein binds to AP2M1 protein]		 CTD PMID:8601816, PMID:31631060 NCBI chr17:5,934,651...6,245,778
Ensembl chr17:5,933,729...6,244,676 		JBrowse link
G Pde4a phosphodiesterase 4A multiple interactions
decreases activity		 ISO [Albuterol co-treated with Rolipram] results in increased expression of PDE4A mRNA
Rolipram results in decreased activity of PDE4A protein		 CTD PMID:10763856, PMID:15922051 NCBI chr 8:22,189,533...22,234,036
Ensembl chr 8:22,189,600...22,233,748 		JBrowse link
G Pde4b phosphodiesterase 4B multiple interactions ISO
EXP		 [Albuterol co-treated with Rolipram] results in increased expression of PDE4B mRNA
Rolipram inhibits the reaction [Manganese results in increased expression of PDE4B protein]
Rolipram inhibits the reaction [Lipopolysaccharides results in increased expression of PDE4B mRNA]		 CTD PMID:10763856, PMID:20384571, PMID:31161640 NCBI chr 5:121,759,236...122,136,814
Ensembl chr 5:121,952,977...122,136,814 		JBrowse link
G Rap1a RAP1A, member of RAS oncogene family multiple interactions EXP Rolipram affects the reaction [Colforsin results in increased activity of RAP1A protein] CTD PMID:10908723 NCBI chr 2:208,193,950...208,215,186
Ensembl chr 2:208,193,954...208,215,187 		JBrowse link
G Rap1b RAP1B, member of RAS oncogene family multiple interactions EXP Rolipram affects the reaction [Colforsin results in increased activity of RAP1B protein] CTD PMID:10908723 NCBI chr 7:60,850,406...60,878,226
Ensembl chr 7:60,853,930...60,860,990 		JBrowse link
G Rapgef3 Rap guanine nucleotide exchange factor 3 multiple interactions
increases expression		 EXP RAPGEF3 mutant form inhibits the reaction [Rolipram results in increased phosphorylation of AKT1 protein]
Rolipram results in increased expression of RAPGEF3 protein		 CTD PMID:18276108 NCBI chr 7:139,232,263...139,254,668
Ensembl chr 7:139,232,251...139,254,551 		JBrowse link
G Sele selectin E multiple interactions ISO [Colforsin co-treated with Rolipram] inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased secretion of SELE protein] CTD PMID:8780174 NCBI chr13:82,355,234...82,365,323
Ensembl chr13:82,355,471...82,365,341 		JBrowse link
G Socs3 suppressor of cytokine signaling 3 multiple interactions
increases expression		 ISO 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein]; [[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein; dorsomorphin inhibits the reaction [[[Colforsin co-treated with Rolipram] results in increased abundance of Cyclic AMP] which results in increased expression of SOCS3 protein]
Rolipram results in increased expression of SOCS3 protein		 CTD PMID:23782265 NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040 		JBrowse link
G Spp1 secreted phosphoprotein 1 multiple interactions EXP Rolipram inhibits the reaction [Oxygen results in increased expression of SPP1 mRNA]; Rolipram inhibits the reaction [Oxygen results in increased expression of SPP1 protein] CTD PMID:18941502 NCBI chr14:6,673,686...6,679,965
Ensembl chr14:6,673,686...6,679,901 		JBrowse link
G Star steroidogenic acute regulatory protein multiple interactions EXP Rolipram promotes the reaction [FSHB protein results in increased expression of STAR mRNA] CTD PMID:25253736 NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases secretion
decreases expression		 ISO
EXP		 Rolipram inhibits the reaction [[Lipopolysaccharides co-treated with deoxynivalenol] results in increased expression of TNF protein]
[Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased expression of SELE protein]; [Colforsin co-treated with Rolipram] inhibits the reaction [TNF protein results in increased secretion of SELE protein]; Rolipram inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Rolipram promotes the reaction [TNF protein results in increased expression of IL6 mRNA]
Rolipram results in decreased secretion of TNF protein
Rolipram results in decreased expression of TNF protein
Rolipram inhibits the reaction [Cyclophosphamide results in increased expression of TNF mRNA]		 CTD PMID:8780174, PMID:8937731, PMID:9819297, PMID:11922776, PMID:15231041, PMID:18710439, PMID:24771768 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19785
    chemical entity 19785
      atom 19782
        nonmetal atom 19657
          nitrogen atom 18539
            nitrogen molecular entity 18539
              organonitrogen compound 18309
                organonitrogen heterocyclic compound 17460
                  pyrrolidines 2223
                    pyrrolidinone 165
                      pyrrolidin-2-ones 140
                        (-)-cotinine + 33
                        (1E)-2-(5-chlorothiophen-2-yl)-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}prop-1-ene-1-sulfonamide 0
                        (2R)-N-hydroxy-2-[(3S)-3-methyl-3-\{4-[(2-methylquinolin-4-yl)methoxy]phenyl\}-2-oxopyrrolidin-1-yl]propanamide 0
                        (2S)-2-[(3S)-3-\{[(6-chloronaphthalen-2-yl)sulfonyl]amino\}-2-oxopyrrolidin-1-yl]-N-(1-methylethyl)-N-\{2-[(methylsulfonyl)amino]ethyl\}propanamide 0
                        (2S)-N-((1S,2R)-2-hydroxy-1-(4-hydroxybenzyl)-3-\{[(8S,11S)-8-[(1S)-1-methylpropyl]-7,10-dioxo-2-oxa-6,9-diazabicyclo[11.2.2]heptadeca-1(15),13,16-trien-11-yl]amino\}propyl)-3-methyl-2-(2-oxopyrrolidin-1-yl)butanamide 0
                        (3S)-1-cyclohexyl-N-(3,5-dichlorophenyl)-5-oxopyrrolidine-3-carboxamide 0
                        (3S)-3-[(2S)-2-amino-3-hydroxybutyl]pyrrolidin-2-one 0
                        (3S)-3-[(2S)-2-amino-3-oxobutyl]pyrrolidin-2-one 0
                        (3S)-3-[(2S)-2-amino-4-hydroxy-3-oxobutyl]pyrrolidin-2-one 0
                        (3S)-N-(3-bromophenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide 0
                        (3S)-N-(3-chloro-2-methylphenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide 0
                        (3S)-N-(5-chloro-2-methylphenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide 0
                        (3Z)-ravenic acid 0
                        (E)-2-(5-chlorothiophen-2-yl)-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}ethenesulfonamide 0
                        (beta-D-glucosyl)-O-mycofactocinone + 0
                        1,5,5-trimethylpyrrolidin-2-one 0
                        1-(4-carboxy-2-guanidinophenyl)-5,5-bis(hydroxymethyl)pyrrolidin-2-one 0
                        1-[4-carboxy-2-(3-pentylamino)phenyl]-5,5-bis(hydroxymethyl)pyrrolidin-2-one 0
                        1-dodecylpyrrolidin-2-one 0
                        2-(5-chlorothiophen-2-yl)-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}ethanesulfonamide 0
                        3-(\{[(2S)-5-oxopyrrolidin-2-yl]methyl\}sulfonyl)-N-[(1S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]-L-alanin[N-(1-cyanocyclopropyl)]amide 0
                        3-amino-5-[(4-hydroxyphenyl)methyl]-4,4-dimethylpyrrolidin-2-one 0
                        3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-\{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl\}-L-phenylalaninamide 0
                        3-nitro-4-(2-oxopyrrolidin-1-yl)benzenesulfonamide 0
                        3-oxo-N-[(3S)-2-oxopyrrolidin-3-yl]dodecanamide 0
                        4-[(2R)-2-(aminomethyl)-2-(hydroxymethyl)-5-oxopyrrolidin-1-yl]-3-[(1-ethylpropyl)amino]benzoic acid 0
                        4-hydroxy-3-[2-oxo-3-(thieno[3,2-b]pyridine-2-sulfonylamino)pyrrolidin-1-ylmethyl]benzamidine 0
                        5-(5-chlorothiophen-2-yl)-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}-1H-1,2,4-triazole-3-sulfonamide 0
                        5-[(4-hydroxyphenyl)methyl]-3-imino-4,4-dimethylpyrrolidin-2-one 0
                        5-\{[(2-amino-9H-purin-6-yl)oxy]methyl\}pyrrolidin-2-one 0
                        5-chloro-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}-1-benzothiophene-2-sulfonamide 0
                        5-chloro-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}-1H-indole-2-sulfonamide 0
                        5-cyclohexylmethyl-2-Pyrrolidinone 0
                        5-oxoproline + 2
                        5-oxopyrrolidine-2-carbaldehyde 0
                        6-chloro-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}-1-benzothiophene-2-sulfonamide 0
                        6-chloro-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}naphthalene-2-sulfonamide 0
                        N-(3-acetamidopropyl)pyrrolidin-2-one 0
                        N-(3-furoyl)-D-valyl-L-valyl-N-((1R,2Z)-4-ethoxy-4-oxo-1-\{[(3S)-2-oxopyrrolidin-3-yl]methyl\}but-2-enyl)-D-leucinamide 0
                        N-(tert-butoxycarbonyl)-L-seryl-L-valyl-N-\{(2S,3E)-5-ethoxy-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl\}-L-leucinamide 0
                        N-Vinyl-2-pyrrolidone 30
                        N-[(2S)-3-cyclohexyl-1-oxo-1-(\{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl\}amino)propan-2-yl]-1H-indole-2-carboxamide 0
                        N-[(3S,6R)-6-\{(S,E)-4-ethoxycarbonyl-1-[(S)-2-oxopyrrolidin-3-yl]but-3-en-2-ylcarbamoyl\}-2,9-dimethyl-4-oxodec-8-en-3-yl]-5-methylisoxazole-3-carboxamide 0
                        N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-\{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl\}-L-leucinamide 0
                        N-[(5-methylisoxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N(1)-((1S)-4-ethoxy-4-oxo-1-\{[(3S)-2-oxopyrrolidin-3-yl]methyl\}but-2-enyl)-L-leucinamide 0
                        N-[(benzyloxy)carbonyl]-O-(tert-butyl)-L-threonyl-3-cyclohexyl-N-[(1S)-2-hydroxy-1-\{[(3S)-2-oxopyrrolidin-3-yl]methyl\}ethyl]-L-alaninamide 0
                        N-\{(3S)-1-[(1-aminoisoquinolin-7-yl)methyl]-2-oxopyrrolidin-3-yl\}thieno[3,2-b]pyridine-2-sulfonamide 0
                        N-methylpyrrolidin-2-one 0
                        PHA-533533 0
                        SG85 0
                        aniracetam 2
                        cotinine N-oxide 0
                        doxapram + 2
                        ethyl (2E,4S)-4-[((2R)-2-\{[N-(tert-butoxycarbonyl)-L-valyl]amino\}-2-phenylethanoyl)amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate 0
                        ethyl (4R)-4-[((2R,5S)-2-(4-fluorobenzyl)-6-methyl-5-\{[(5-methylisoxazol-3-yl)carbonyl]amino\}-4-oxoheptanoyl)amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pentanoate 0
                        fradafiban + 0
                        ivosidenib 0
                        lefradafiban 0
                        levetiracetam 41
                        lilaline 0
                        melophlin P 0
                        melophlin Q 0
                        melophlin R 0
                        melophlin S 0
                        premycofactocin + 0
                        pyranonigrin I 0
                        pyranonigrin J 0
                        pyrrolidin-2-one 0
                        rolapitant 0
                        rolipram + 39
                        sch 210971 0
                        sch 210972 + 0
                        sch 213766 0
                        tenuazonic acid 0
                        tert-butyl N-\{1-[(1S)-1-\{[(1R,2S)-1-(benzylcarbamoyl)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl\}-2-cyclopropylethyl]-2-oxopyridin-3-yl\}carbamate 0
                        trans-3-hydroxycotinine + 0
                        trans-3-hydroxycotinine beta-D-glucuronide 0
                        vibrioferrin 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19785
    subatomic particle 19782
      composite particle 19782
        hadron 19782
          baryon 19782
            nucleon 19782
              atomic nucleus 19782
                atom 19782
                  main group element atom 19670
                    p-block element atom 19670
                      carbon group element atom 19572
                        carbon atom 19561
                          organic molecular entity 19561
                            organic group 18493
                              organic divalent group 18486
                                organodiyl group 18486
                                  carbonyl group 18389
                                    carbonyl compound 18389
                                      carboxylic acid 18060
                                        carboacyl group 17346
                                          univalent carboacyl group 17346
                                            carbamoyl group 17132
                                              carboxamide 17132
                                                lactam 8026
                                                  gamma-lactam 6265
                                                    pyrrolidin-2-ones 140
                                                      (-)-cotinine + 33
                                                      (1E)-2-(5-chlorothiophen-2-yl)-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}prop-1-ene-1-sulfonamide 0
                                                      (2R)-N-hydroxy-2-[(3S)-3-methyl-3-\{4-[(2-methylquinolin-4-yl)methoxy]phenyl\}-2-oxopyrrolidin-1-yl]propanamide 0
                                                      (2S)-2-[(3S)-3-\{[(6-chloronaphthalen-2-yl)sulfonyl]amino\}-2-oxopyrrolidin-1-yl]-N-(1-methylethyl)-N-\{2-[(methylsulfonyl)amino]ethyl\}propanamide 0
                                                      (2S)-N-((1S,2R)-2-hydroxy-1-(4-hydroxybenzyl)-3-\{[(8S,11S)-8-[(1S)-1-methylpropyl]-7,10-dioxo-2-oxa-6,9-diazabicyclo[11.2.2]heptadeca-1(15),13,16-trien-11-yl]amino\}propyl)-3-methyl-2-(2-oxopyrrolidin-1-yl)butanamide 0
                                                      (3S)-1-cyclohexyl-N-(3,5-dichlorophenyl)-5-oxopyrrolidine-3-carboxamide 0
                                                      (3S)-3-[(2S)-2-amino-3-hydroxybutyl]pyrrolidin-2-one 0
                                                      (3S)-3-[(2S)-2-amino-3-oxobutyl]pyrrolidin-2-one 0
                                                      (3S)-3-[(2S)-2-amino-4-hydroxy-3-oxobutyl]pyrrolidin-2-one 0
                                                      (3S)-N-(3-bromophenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide 0
                                                      (3S)-N-(3-chloro-2-methylphenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide 0
                                                      (3S)-N-(5-chloro-2-methylphenyl)-1-cyclohexyl-5-oxopyrrolidine-3-carboxamide 0
                                                      (3Z)-ravenic acid 0
                                                      (E)-2-(5-chlorothiophen-2-yl)-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}ethenesulfonamide 0
                                                      (beta-D-glucosyl)-O-mycofactocinone + 0
                                                      1,5,5-trimethylpyrrolidin-2-one 0
                                                      1-(4-carboxy-2-guanidinophenyl)-5,5-bis(hydroxymethyl)pyrrolidin-2-one 0
                                                      1-[4-carboxy-2-(3-pentylamino)phenyl]-5,5-bis(hydroxymethyl)pyrrolidin-2-one 0
                                                      1-dodecylpyrrolidin-2-one 0
                                                      2-(5-chlorothiophen-2-yl)-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}ethanesulfonamide 0
                                                      3-(\{[(2S)-5-oxopyrrolidin-2-yl]methyl\}sulfonyl)-N-[(1S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]-L-alanin[N-(1-cyanocyclopropyl)]amide 0
                                                      3-amino-5-[(4-hydroxyphenyl)methyl]-4,4-dimethylpyrrolidin-2-one 0
                                                      3-fluoro-Nalpha-(1H-indol-2-ylcarbonyl)-N-\{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl\}-L-phenylalaninamide 0
                                                      3-nitro-4-(2-oxopyrrolidin-1-yl)benzenesulfonamide 0
                                                      3-oxo-N-[(3S)-2-oxopyrrolidin-3-yl]dodecanamide 0
                                                      4-[(2R)-2-(aminomethyl)-2-(hydroxymethyl)-5-oxopyrrolidin-1-yl]-3-[(1-ethylpropyl)amino]benzoic acid 0
                                                      4-hydroxy-3-[2-oxo-3-(thieno[3,2-b]pyridine-2-sulfonylamino)pyrrolidin-1-ylmethyl]benzamidine 0
                                                      5-(5-chlorothiophen-2-yl)-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}-1H-1,2,4-triazole-3-sulfonamide 0
                                                      5-[(4-hydroxyphenyl)methyl]-3-imino-4,4-dimethylpyrrolidin-2-one 0
                                                      5-\{[(2-amino-9H-purin-6-yl)oxy]methyl\}pyrrolidin-2-one 0
                                                      5-chloro-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}-1-benzothiophene-2-sulfonamide 0
                                                      5-chloro-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}-1H-indole-2-sulfonamide 0
                                                      5-cyclohexylmethyl-2-Pyrrolidinone 0
                                                      5-oxoproline + 2
                                                      5-oxopyrrolidine-2-carbaldehyde 0
                                                      6-chloro-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}-1-benzothiophene-2-sulfonamide 0
                                                      6-chloro-N-\{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl\}naphthalene-2-sulfonamide 0
                                                      N-(3-acetamidopropyl)pyrrolidin-2-one 0
                                                      N-(3-furoyl)-D-valyl-L-valyl-N-((1R,2Z)-4-ethoxy-4-oxo-1-\{[(3S)-2-oxopyrrolidin-3-yl]methyl\}but-2-enyl)-D-leucinamide 0
                                                      N-(tert-butoxycarbonyl)-L-seryl-L-valyl-N-\{(2S,3E)-5-ethoxy-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl\}-L-leucinamide 0
                                                      N-Vinyl-2-pyrrolidone 30
                                                      N-[(2S)-3-cyclohexyl-1-oxo-1-(\{(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl\}amino)propan-2-yl]-1H-indole-2-carboxamide 0
                                                      N-[(3S,6R)-6-\{(S,E)-4-ethoxycarbonyl-1-[(S)-2-oxopyrrolidin-3-yl]but-3-en-2-ylcarbamoyl\}-2,9-dimethyl-4-oxodec-8-en-3-yl]-5-methylisoxazole-3-carboxamide 0
                                                      N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-\{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl\}-L-leucinamide 0
                                                      N-[(5-methylisoxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N(1)-((1S)-4-ethoxy-4-oxo-1-\{[(3S)-2-oxopyrrolidin-3-yl]methyl\}but-2-enyl)-L-leucinamide 0
                                                      N-[(benzyloxy)carbonyl]-O-(tert-butyl)-L-threonyl-3-cyclohexyl-N-[(1S)-2-hydroxy-1-\{[(3S)-2-oxopyrrolidin-3-yl]methyl\}ethyl]-L-alaninamide 0
                                                      N-\{(3S)-1-[(1-aminoisoquinolin-7-yl)methyl]-2-oxopyrrolidin-3-yl\}thieno[3,2-b]pyridine-2-sulfonamide 0
                                                      N-methylpyrrolidin-2-one 0
                                                      PHA-533533 0
                                                      SG85 0
                                                      aniracetam 2
                                                      cotinine N-oxide 0
                                                      doxapram + 2
                                                      ethyl (2E,4S)-4-[((2R)-2-\{[N-(tert-butoxycarbonyl)-L-valyl]amino\}-2-phenylethanoyl)amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pent-2-enoate 0
                                                      ethyl (4R)-4-[((2R,5S)-2-(4-fluorobenzyl)-6-methyl-5-\{[(5-methylisoxazol-3-yl)carbonyl]amino\}-4-oxoheptanoyl)amino]-5-[(3S)-2-oxopyrrolidin-3-yl]pentanoate 0
                                                      fradafiban + 0
                                                      ivosidenib 0
                                                      lefradafiban 0
                                                      levetiracetam 41
                                                      lilaline 0
                                                      melophlin P 0
                                                      melophlin Q 0
                                                      melophlin R 0
                                                      melophlin S 0
                                                      premycofactocin + 0
                                                      pyranonigrin I 0
                                                      pyranonigrin J 0
                                                      pyrrolidin-2-one 0
                                                      rolapitant 0
                                                      rolipram + 39
                                                      sch 210971 0
                                                      sch 210972 + 0
                                                      sch 213766 0
                                                      tenuazonic acid 0
                                                      tert-butyl N-\{1-[(1S)-1-\{[(1R,2S)-1-(benzylcarbamoyl)-1-hydroxy-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]carbamoyl\}-2-cyclopropylethyl]-2-oxopyridin-3-yl\}carbamate 0
                                                      trans-3-hydroxycotinine + 0
                                                      trans-3-hydroxycotinine beta-D-glucuronide 0
                                                      vibrioferrin 0
paths to the root

Contact Us |  About Us |  License CC BY 4.0 |  Legal Disclaimer |  © Medical College of Wisconsin
NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.